Human metabolism of nebicapone (BIA 3-202), a novel catechol-O- methyltransferase inhibitor: Characterization of in vitro glucuronidation

Drug Metabolism and Disposition

Volumn 34, Issue 11, 2006, Pages 1856-1862

  Loureiro, A I ^a   Bonifacio M J ^a   Fernandes Lopes, C ^a   Almeida, L ^a   Wright, L C ^a   Soares Da Silva, P ^a  

^a DEPARTMENT OF RESEARCH AND DEVELOPMENT   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

1 (3 O BETA DEXTRO GLUCOPYRANURONOSIDO 4 HYDROXY 5 NITROPHENYL) 2 PHENYLETHANONE; 1 (3,4 DIHYDROXY 5 NITROPHENYL) 2 PHENYLETHANONE; 1 (4 HYDROXY 3 METHOXY 5 NITROPHENYL) 2 PHENYLETHANONE; 1 (5 ACETAMIDO 3,4 DIHYDROXYPHENYL) 2 PHENYLETHANONE; BIA 3 465; BIA 3 467; BIA 3 476; CATECHOL METHYLTRANSFERASE INHIBITOR; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLYCOSYLTRANSFERASE; NEBICAPONE; PYRIDINIUM 1 (4 HYDROXY 5 NITRO 3 O SULFATOPHENYL) 2 PHENYLETHANONE; UDP GLUCURONOSYLTRANSFERASE 1A10; UDP GLUCURONOSYLTRANSFERASE 1A3; UDP GLUCURONOSYLTRANSFERASE 1A6; UDP GLUCURONOSYLTRANSFERASE 1A7; UDP GLUCURONOSYLTRANSFERASE 1A8; UDP GLUCURONOSYLTRANSFERASE 1A9; UDP GLUCURONOSYLTRANSFERASE 2B15; UDP GLUCURONOSYLTRANSFERASE 2B7; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; METHYLATION; NORMAL HUMAN; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

ACETOPHENONES; ADMINISTRATION, ORAL; AREA UNDER CURVE; CATECHOL O-METHYLTRANSFERASE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME INHIBITORS; FEMALE; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; MALE; MASS SPECTROMETRY; MICROSOMES; MICROSOMES, LIVER; MOLECULAR STRUCTURE; RECOMBINANT PROTEINS;

EID: 33751107236     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.010447     Document Type: Article

References (26)

1. Almeida L and Soares-Da-Silva P (2003) Pharmacokinetics and pharmacodynamics of BIA 3-202, a novel COMT inhibitor, during first administration to humans. Drugs Res Dev 4:207-217.
2. Almeida L, Vaz-da-Silva M, Silveira P, Falcao A, Maia J, Loureiro A, Torrao L, Machado R, Wright L, and Soares-da-Silva P (2004) Pharmacokinetic- pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. Clin Neuropharmacol 27:17-24.
3. Antonio L, Xu J, Little JM, Burchell B, Magdalou J, and Radominska-Pandya A (2003) Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9, and UGT2B7. Arch Biochem Biophys 411:251-261.
4. Backstrom R, Honkanen E, Pippuri A, Kairisalo P, Pystynen J, Heinola K, Nissinen E, Linden IB, Mannisto PT, Kaakkola S, et al. (1989) Synthesis of some novel potent and selective catechol O-methyltransferase inhibitors. J Med Chem 32:841-846.
5. Basu NK, Ciotti M, Hwang MS, Kole L, Mitra PS, Cho JW, and Owens IS (2004) Differential and special properties of the major human UGT1-encoded gastrointestinal UDP-glucuronosyltransferases enhance potential to control chemical uptake. J Biol Chem 279:1429-1441.
6. Chung JY, Cho JY, Yu KS, Kim JR, Jung HR, Lim KS, Jang IJ, and Shin SG (2005) Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther 77:486-494.
7. Dingemanse J (1997) Catechol O-methyltransferase inhibitors: clinical potential in the treatment of Parkinson's disease. Drug Dev Res 42:1-25.
8. Dingemanse J, Jorga K, Zurcher G, Schmitt M, Sedek G, Da Prada M, and Van Brummelen P (1995) Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 40:253-262.
9. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
10. Heikkinen H, Nutt JG, LeWitt PA, Koller WC, and Gordin A (2001) The effects of different repeated doses of entacapone on the pharmacokinetics of L-dopa and on the clinical response to L-dopa in Parkinson's disease. Clin Neuropharmacol 24:150-157.
11. Heikkinen H, Varhe A, Laine T, Puttonen J, Kela M, Kaakkola S, and Reinikainen K (2002) Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. Br J Clin Pharmacol 54:363-371.
12. Houston JB and Kenworthy KE (2000) In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
13. Hutzler JM and Tracy TS (2002) Atypical kinetic profiles in drug metabolism reactions. Drug Metab Dispos 30:355-362.
14. Jorga K, Fotteler B, Heizmann P, and Gasser R (1999) Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase. Br J Clin Pharmacol 48:513-520.
15. Keranen T, Gordin A, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Schultz E, Seppala L, and Wikberg T (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46:151-157.
16. Kiang TK, Ensom MH, and Chang TK (2005) UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106:97-132.
17. Lautala P, Ethell BT, Taskinen J, and Burchell B (2000) The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 28:1385-1389.
18. Lautala P, Kivimaa M, Salomies H, Elovaara E, and Taskinen J (1997) Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes. Pharm Res (NY) 14:1444-1448.
19. Marsh S and McLeod HL (2004) Pharmacogenetics of irinotecan toxicity. Pharmacogenomics 5:835-843.
20. Massacesi C, Terrazzino S, Marcucci F, Rocchi MB, Lippe P, Bisonni R, Lombardo M, Pilone A, Mattioli R, and Leon A (2006) Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy. Cancer 106:1007-1016.
21. Miners JO, Smith PA, Sorich MJ, McKinnon RA, and Mackenzie PI (2004) Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol 44:1-25.
22. Silveira P, Vaz-Da-Silva M, Almeida L, Maia J, Falcao A, Loureiro A, Torrao L, Machado R, Wright L, and Soares-Da-Silva P (2003) Pharmacokinetic- pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/benserazide. Eur J Clin Pharmacol 59:603-609.
23. Strassburg CP, Kneip S, Topp J, Obermayer-Straub P, Barut A, Tukey RH, and Manns MP (2000) Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 275:36164-36171.
24. Strassburg CP, Nguyen N, Manns MP, and Tukey RH (1998) Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium. Mol Pharmacol 54:647-654.
25. Taskinen J, Ethell BT, Pihlavisto P, Hood AM, Burchell B, and Coughtrie MW (2003) Conjugation of catechols by recombinant human sulfotransferases, UDP-glucuronosyltransferases, and soluble catechol O-methyltransferase: structure-conjugation relationships and predictive models. Drug Metab Dispos 31:1187-1197.
26. Wikberg T, Vuorela A, Ottoila P, and Taskinen J (1993) Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 21:81-92.